Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CKD Anemia Clear all
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

NCT05082584
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 9, 2026, 11:37 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed No phase listed Observational

Erythropoietin Resistance in Anemia of Chronic Kidney Disease

NCT00526747
View directory record Official record
Conditions
Anemia, Kidney Failure, Erythropoietin
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Comparison Between Effects of Two Iron Preparations on Protein in the Urine

NCT00534144
View directory record Official record
Conditions
Kidney Failure, Chronic, Anemia, Iron-Deficiency
Interventions
iron sucrose injection, USP, sodium ferric gluconate complex in sucrose injection
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Phoenix, Arizona • Alhambra, California • Bell Gardens, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

NCT00761657
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
34
States / cities
Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 9, 2026, 11:37 PM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

NCT00830037
View directory record Official record
Conditions
Chronic Kidney Disease, Iron-deficiency Anemia
Interventions
IV Iron, Ferrous Sulfate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

NCT00236977
View directory record Official record
Conditions
Anemia
Interventions
Venofer, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Valley Forge, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

NCT00090753
View directory record Official record
Conditions
Anemia
Interventions
Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
83
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

NCT02412449
View directory record Official record
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

NCT00081484
View directory record Official record
Conditions
Anemia
Interventions
epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Covina, California • Los Alamitos, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

NCT00752609
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, GSK1278863 matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 9, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

Mechanisms of EPO-induced Hypertension

NCT03810911
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Anemia
Interventions
Darbepoetin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

NCT06901505
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Erythropoiesis-Stimulating Agent (ESA), Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
18
States / cities
Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

NCT01977573
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Azusa, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 9, 2026, 11:37 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

NCT02174731
View directory record Official record
Conditions
Anemia
Interventions
Roxadustat, Epoetin alfa
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
51
States / cities
Huntsville, Alabama • El Centro, California • Fairfield, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 9, 2026, 11:37 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01235936
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Augusta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 9, 2026, 11:37 PM EDT
Recruiting Phase 4 Interventional

Oral Iron in Children With Chronic Kidney Disease

NCT03991169
View directory record Official record
Conditions
Chronic Kidney Insufficiency, Chronic Kidney Diseases
Interventions
Ferrous Sulfate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

NCT02327546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548, Ferrous Sulfate
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 9, 2026, 11:37 PM EDT